Adocia (LTS:0QAI) Quality Rank


LTS:0QAI Adocia LTS:0QAI
44 GF Score
Price €3.81
GF Value €0.88
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Adocia Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Adocia Quality Rank Related Terms

LTS:0QAI
44GF Score
Adocia LTS:0QAI
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Adocia (LTS:0QAI) Overvalued in 2026?

Based on GuruFocus' analysis, Adocia stock appears to be overvalued. The current stock price of €3.81 is trading 332.7% above its estimated GF Value™ of €0.88. GuruFocus considers Adocia to be Significantly Overvalued.

Key valuation signals for LTS:0QAI:

  • Quality Rank:
  • GF Value™: €0.88 vs. price of €3.81 (332.7% above fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the LTS:0QAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adocia Business Description

Other Exchanges ADOC:FranceA89:Germany
Address 115 Avenue Lacassagne, Lyon, FRA, 69003
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
44GF Score

Get the complete analysis for LTS:0QAI

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.81
Price
€0.88
GF Value